BlackThorn Therapeutics Inc. put its $54m in series A venture capital funding to work, emerging with a refined artificial intelligence and machine learning (AI/ML) platform for the development of personalized medicines to treat neurobehavioral disorders and with a drug in the clinic. On 13 June, the company said it has raised $76m in series B cash to advance its lead drug candidate and take a second program into human studies.
San Francisco-based BlackThorn launched in October 2016 with a $40m series A round that was expanded a few months later...






